Shigatse

Researchers are investigating whether a new management strategy for hypertension that combines usual care visits with the use of the ESH CARE App improves blood pressure control and related health outcomes compared to standard care. This one-year, randomized study aims to assess differences in office, home, and ambulatory blood pressure control, as well as cardiovascular and kidney-related measures in patients with uncontrolled hypertension. Participants are randomly assigned to one of two groups the usual care group, which receives standard three-monthly visits with therapy adjusted based on office blood pressure, and the POST-strategy group, which adds use of the ESH CARE App to communicate home blood pressure readings to a referral center. In the POST group, therapy adjustments occur every 15 days based on home measurements. Both groups undergo regular visits at baseline, three, six, and twelve months with clinical assessments, blood tests, urine tests, echocardiograms, ECGs, and ambulatory blood pressure monitoring. Throughout the study, participants measure home blood pressure regularly, with the POST group measuring twice weekly plus seven consecutive days before visits, and the usual care group measuring before baseline and study end. Researchers monitor blood pressure changes, heart structure, kidney function, and medication use to evaluate the effects of each strategy. The total participation lasts about one year, with detailed clinical and laboratory evaluations at scheduled intervals to assess treatment impact and safety.

Researchers are evaluating the safety and effectiveness of gotistobart ONC-392BNT316, a next-generation anti-CTLA-4 antibody, in patients with metastatic non-small cell lung cancer NSCLC whose disease has progressed after treatment with anti-PD-1 or PD-L1 antibody-based therapies. This Phase 3 clinical trial aims to compare gotistobart with the chemotherapy drug docetaxel to see if it can help prolong life in these patients. Approximately 630 patients will participate, and the study is divided into two stages to confirm dosing and assess outcomes. In Stage I, two dosing regimens of gotistobart will be tested against docetaxel, which is given at 75 mgm2 every 21 days. Gotistobart will be administered by intravenous infusion over 60 minutes every 21 days, either at 3 mgkg or 6 mgkg with two loading doses of 10 mgkg. After selecting the most appropriate dosing regimen, Stage II will compare that gotistobart dose with docetaxel in patients with squamous cell NSCLC. Treatment will continue for up to 17 cycles, approximately one year. Participants will receive regular infusions and be monitored for overall survival over 36 months, along with secondary outcomes like tumor response, progression-free survival, and treatment-related adverse events. Patients must have measurable tumors and meet specific health criteria before joining. The study includes safety monitoring and ongoing assessments to evaluate how well the treatments are tolerated and their effects on cancer progression.